Where it is registered
Each register with its number of medicines and a few of them.
United States
FDA · 7 medicines
- Aliskiren Hemifumarate150MG BASE, 300MG BASE · tablet · PH Health
- Tekturna150MG BASE, 300MG BASE · tablet · Lxo Ireland
- Tekturna37.5MG BASE · capsule, pellet · Noden Pharma
- Amturnide150MG BASE; 5MG BASE; 12.5MG, 300MG BASE; 10MG BASE; 12.5MG, 300MG BASE; 10MG BASE; 25MG … · tablet · Novartis
Brazil
Anvisa · 5 medicines
- hemifumarato de alisquirenoEms S/A
- RasilezNovartis Biociencias S.A
- Rasilez AmloNovartis Biociencias S.A
- Rasilez AmloNovartis Biociencias S.A
European Union
EMA · 1 medicine · Historical list
All medicines with Aliskiren hemifumarate
Every register, a page at a time. Strengths and packs are on each medicine’s page.
13 results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Aliskiren Hemifumarate | United States | 150MG BASE, 300MG BASE | tablet | Marketed | PH Health |
| Tekturna | United States | 150MG BASE, 300MG BASE | tablet | Marketed | Lxo Ireland |
| hemifumarato de alisquireno | Brazil | Authorised | Ems S/A | ||
| AmturnideCombination | United States | 150MG BASE; 5MG BASE; 12.5MG, 300MG BASE; 10MG BASE; 12.5MG, 300MG BASE; 10MG BASE; 25MG … | tablet | Not marketed | Novartis |
| Tekturna HCTCombination | United States | 150MG BASE; 12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, 150MG BASE; 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, 300MG BASE; 12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectivene | tablet | Not marketed | Noden Pharma |
| TekamloCombination | United States | 150MG BASE; 10MG BASE, 150MG BASE; 5MG BASE, 300MG BASE; 10MG BASE … | tablet | Not marketed | Novartis |
| Tekturna | United States | 37.5MG BASE | capsule, pellet | Not marketed | Noden Pharma |
| ValturnaCombination | United States | 150MG BASE; 160MG, 300MG BASE; 320MG | tablet | Not marketed | Novartis |
| RasilamloCombination | European Union | Withdrawn | Novartis Europharm Ltd | ||
| Rasilez HCTCombination | Brazil | Cancelled | Novartis Biociencias S.A | ||
| Rasilez AmloCombination | Brazil | Cancelled | Novartis Biociencias S.A | ||
| Rasilez AmloCombination | Brazil | Cancelled | Novartis Biociencias S.A | ||
| Rasilez | Brazil | Cancelled | Novartis Biociencias S.A |
Brand names
The same brand on several registers.
Companies
The companies holding its medicines, the most first.
Often combined with
Substances it shares a medicine with.
Names in the registers
How the registers write it, in their own languages.
- Hemifumarato alisquireno
Sources
Compiled by Prognia from the public medicine registers of Anvisa, EMA and FDA. Each medicine’s page names its own source, licence and attribution.
Report an error or request removalCorrections from a register or a company are welcome.
For reference and learning, not treatment advice. Always check the official product information.
At a glance
- Registers
- 3
- Medicines
- 13
- Companies
- 7



